For those of us who have been in the field for decades, this cycle of exhilaration or despair is common and manageable, but recent months have raised even further uncertainty about how progress in ...

Thus, many of the featured studies seek to overcome ... Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), told The American Journal of Managed Care ® in an interview ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Dr. Michael Gold’s passion is research. More specifically gynecological cancer research. As a gynecological oncologist at ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent ... But there might be other [predictive factors] that will ...

The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043SAN DIEGO, April 23, 2025 ...

SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...